Provisional Table of Contents
EXECUTIVE SUMMARY
Chapter 1 Pharmaceutical business model and strategies
- 1.1 The Blockbuster Model – If it isn' t broken don' t fix it?
Chapter 2 The emergence of personalized medicine
- 2.1 The right drug for the right disease
- 2.2 The right drug for the right patient
- 2.3 Single Nucleotide Polymorphisms and Haplotypes
- 2.4 Herceptin and Breast Cancer
- 2.5 Beyond cancer – expanding the potential for personalized
medicine
- 2.6 Prevention and prediction of disease predisposition
- 2.7 Business implications of pursuing personalized medicine
- 2.8 Pharmacogenomics and impact on drug development costs
- 2.9 Personalised medicine and the drug pipeline 31
- 2.10 Genomics and the probability of reducing attrition rates
- 2.11 The rise of the biotechnology industry 35
Chapter 3 Bridging the pharma-device-diagnostics divide–tapping the
potential
- 3.1 The Medical Device Industry
- 3.1.1. Medical devices and therapeutics
- 3.1.2 Combination drug-device products
- 3.1.3 Angiotech and combination products
- 3.1.4 Medtronic and combination product development.
- 3.1.5 Targeting the eye
- 3.2 The Medical Diagnostics Industry
- 3.2.1 Pharmacogenomics to push pharma-diagnostic collaborations.
Chapter 4 Evaluation methodologies of suitable licensing candidates
- 4.1 Market size analysis
- 4.2 Market size estimation for targeted therapies
- 4.3 Evaluation methodologies and models
- 4.4 Discounted cash flow
- 4.5 Decision analysis
- 4.6 Decision analysis output
- 4.7 Sensitivity Analysis
- 4.8 Sensitivity analysis on values
- 4.9 Sensitivity analysis on probabilities
- 4.10 Value of Information
- 4.11 Value of perfect information
- 4.12 Value of imperfect information
- 4.13 Real Options
Chapter 5 Conclusion |
Related Report
|
View Cart
